Paper Details

This article provides a systematic comparison of the efficacy and safety of Modified Electroconvulsive Therapy (ECT) versus esKetamine for treating treatment-resistant depression (TRD) and anxiety disorders. TRD and anxiety are challenging to treat, leading clinicians to explore advanced options like Modified ECT and esKetamine. The review evaluates the effectiveness, safety profiles, mechanisms of action, and patient outcomes of both treatments. esKetamine is noted for its rapid onset of effects, providing significant symptom relief within hours to days, although requiring maintenance dosing. Modified ECT, with its well-documented long-term efficacy, often outperforms pharmacological treatments but is associated with cognitive side effects. Safety concerns for esKetamine include dissociative symptoms and cardiovascular effects, while ECT's risks are mitigated by modern anesthetic techniques. The distinct mechanisms of action and patient outcomes underscore the importance of personalized treatment strategies, considering individual needs and clinical contexts to optimize therapeutic benefits and minimize risks

TrdD; anxiety; modECT, esKetamine.